Join the club for FREE to access the whole archive and other member benefits.

SRF to develop glucosepane-cleaving antibodies with Spiegel Lab


Key points from article :

SENS Research Foundation announced a new research program in collaboration with the Spiegel lab at Yale University.

One suspected reason we age is the accumulation of sugary metabolic wastes known as advanced glycation end-products (AGEs).

AGEs, such as glucosepane, form cross-links, binding together important proteins and preventing them from moving.

Glucosepane is very hard for the body to break down, and it can last several decades once formed.

Cross-links degrade the elastic properties of skin and blood vessel walls.

The SENS solution is to find ways to break down the crosslinks, thus freeing up the trapped proteins and restoring tissue elasticity.

In 2015, with funding from the SENS Research Foundation, the Spiegel lab created glucosepane to test drugs and therapies on.

The lab is now developing the first monoclonal anti-glucosepane antibodies towards glucosepane-cleaving therapies.

Monoclonal anti-glucosepane antibodies has huge implications for treating age-related diseases.

Anti-glucosepane antibodies may offer new therapies for age-related diseases

Mentioned in this article:

Tap on icon for description, click on resource name for more details.


Non-profit organization focused on transforming the way the world researches and treats age-related diseases


Research group at Yale university developing synthetic complex molecular targets